Master10
Public Health, Nutrition & Epidemics18 Concepts & Facts

JIPMER Genomic Tuberculosis Diagnostics Initiative GK Facts, Overview & Study Guide

Reviewed by the Master10 Editorial Board for accuracy, clarity and competitive-exam relevance.Editorial Policy
The Genomic Tuberculosis Diagnostics Initiative at JIPMER (Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry) is an advanced molecular epidemiology and precision microbiology programme deploying Whole Genome Sequencing (WGS) and Targeted Next-Generation Sequencing (tNGS) directly onto clinical sputum and extrapulmonary samples to rapidly decode drug-resistance mutations across **Mycobacterium tuberculosis (Mtb) strains. Operating as an Institute of National Importance (INI) under the Ministry of Health and Family Welfare (governed by the JIPMER Puducherry Act, 2008), JIPMER's Regional Mycobacteriology and Genomic Sequencing Reference Laboratory addresses the single greatest bottleneck in India's National Tuberculosis Elimination Programme (NTEP): the multi-week delay required by conventional phenotypic liquid culture (MGIT-960, taking 4 to 8 weeks) and the limited mutation scope of rapid cartridge assays (CBNAAT / GeneXpert and TrueNat*, which primarily screen only the rpoB gene for Rifampicin resistance). Through high-throughput Illumina and Oxford Nanopore sequencing pipelines aligned with the World Health Organization (WHO) Catalogue of Mutations in Mycobacterium tuberculosis Complex, the JIPMER genomic initiative simultaneously screens over 15 anti-tubercular drug targets in a single diagnostic workflow within 48 to 72 hours. This includes first-line drugs (Rifampicin via rpoB, Isoniazid via katG and inhA, Ethambutol via embB, and Pyrazinamide via pncA), fluoroquinolones (Levofloxacin/Moxifloxacin via gyrA and gyrB), and newer oral BPaLM regimen drugs (Bedaquiline via Rv0678/atpE, Pretomanid, and Linezolid via rplC/rrl). By generating a complete genomic resistance profile before treatment initiation, clinicians immediately place patients on personalized all-oral regimens rather than risking treatment failure. At the national public health level, JIPMER functions as a southern regional hub under the Indian Tuberculosis Genomic Surveillance Consortium (InTGS)—modeled on the COVID-19 INSACOG network—and feeds real-time lineage data (such as the prevalence of the Indo-Oceanic Lineage 1 / East African-Indian and Beijing Lineage 2 clades) into the Ni-kshay digital surveillance portal. This genomic vigilance directly powers the Pradhan Mantri TB Mukt Bharat Abhiyaan* as India accelerates toward eliminating tuberculosis ahead of the UN Sustainable Development Goal (SDG 3.3) deadline of 2030.

Key Concepts & Self-Assessment18 Key Facts

Review key JIPMER Genomic Tuberculosis Diagnostics Initiative exam facts and rate your mastery to track revision.

Progress: 0/18 Rated 0 Mastered 0 Review Later
#1
Nodal Institution & Statutory Status: JIPMER (Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry)—tracing its origins to the École de Médecine de Pondichéry established by the French Government in 1823—was declared an Institute of National Importance (INI) under the JIPMER Puducherry Act, 2008.
#2
Causative Pathogen of Tuberculosis: *Mycobacterium tuberculosis, an obligate aerobic, slow-growing, non-motile acid-fast bacillus (AFB) discovered on 24 March 1882 by German physician Robert Koch (1905 Nobel Prize); its cell wall is rich in waxy Mycolic Acids requiring Ziehl-Neelsen staining*.
#3
Advantage of tNGS / WGS over CBNAAT (GeneXpert): While CBNAAT and indigenous TrueNat (developed by Molbio Diagnostics, Goa) only detect M. tuberculosis and *Rifampicin resistance (rpoB gene), Genomic Sequencing (WGS/tNGS) simultaneously detects resistance across 13 to 18 first-line, second-line, and novel drugs* in one run.
#4
Core Genetic Resistance Markers Decoded: Rifampicin (rpoB 81-bp RRDR region), Isoniazid (katG S315T high-level resistance & inhA promoter mutation), Pyrazinamide (pncA), Ethambutol (embB), Fluoroquinolones (gyrA/gyrB), and Bedaquiline (Rv0678 efflux regulator).
#5
Statutory Classification — MDR-TB, Pre-XDR-TB & XDR-TB (WHO 2021 Revised Definitions): MDR-TB = resistance to at least Isoniazid and Rifampicin; Pre-XDR-TB = MDR/RR-TB plus resistance to any Fluoroquinolone; XDR-TB = Pre-XDR-TB plus resistance to at least one additional Group A drug (Bedaquiline or Linezolid).
#6
Introduction of the All-Oral 6-Month BPaLM Regimen in India (2024): NTEP rolled out the 4-drug BPaLM regimen (Bedaquiline + Pretomanid + Linezolid + Moxifloxacin), cutting MDR-TB treatment duration from 18–24 months down to just 6 months (26 weeks) with ~89% success.
#7
Indian Tuberculosis Genomic Surveillance Consortium (InTGS): Launched on World TB Day (24 March 2022) by the Department of Biotechnology (DBT) and MoHFW to sequence 32,500+ clinical Mtb isolates across India to map lineage mutations.
#8
Predominant Mtb Lineages in India: Genomic mapping reveals that Southern India (including Puducherry and Tamil Nadu) is dominated by the ancient Lineage 1 (Indo-Oceanic / EAI clade), whereas Northern and Northeastern India show higher proportions of Lineage 3 (CAS/Delhi) and hyper-virulent Lineage 2 (Beijing clade).
#9
Pradhan Mantri TB Mukt Bharat Abhiyaan (2022): Launched by President Droupadi Murmu on 9 September 2022, introducing the Ni-kshay Mitra community crowd-support initiative where citizens/corporates adopt TB patients for nutritional baskets.
#10
Ni-kshay Poshan Yojana (NPY) Financial Revision (Nov 2024): Direct Benefit Transfer (DBT) nutritional support for all notified TB patients under NTEP was doubled from ₹500 per month to ₹1,000 per month (providing ₹6,000 over a 6-month treatment course) effective 1 November 2024.
#11
India's TB Elimination Target vs UN SDG 3.3: India committed to achieving TB elimination by 2025/2026—five years ahead of the global UN Sustainable Development Goal (SDG 3.3) target of 2030.
#12
WHO Global TB Report 2024 Milestone for India: Documented a 17.7% decline in TB incidence in India between 2015 and 2023 (from 237 to 195 per lakh population)—more than double the global average rate of decline (8.3%).
#13
Mandatory TB Notification Law (2012 & 2018): The Ministry of Health and Family Welfare declared Tuberculosis a mandatorily notifiable disease in May 2012; failing to report TB cases by private doctors, chemists, or labs is punishable under Sections 269 and 270 of the IPC (now Bharatiya Nyaya Sanhita).
#14
BCG Vaccine & Adult Revaccination Trial: The classic Bacillus Calmette–Guérin (BCG) live attenuated Mycobacterium bovis vaccine (1921) protects children against tubercular meningitis; India is also evaluating recombinant VPM1002 and Immuvac (MIP) vaccines.
#15
Culture Turnaround Time Reduction: Conventional Löwenstein–Jensen (LJ) solid medium requires up to 8 weeks and liquid MGIT-960 requires 2–6 weeks, whereas culture-free Targeted Next-Generation Sequencing (tNGS) directly on sputum delivers a pan-drug resistome in 48–72 hours.
#16
Detection of Heteroresistance & Mixed Infections: Genomic deep sequencing detects minor mutant sub-populations (heteroresistance down to 1%–5% allele frequency) that standard phenotypic DST completely misses.
#17
Nodal Research Alignment with ICMR-NIRT: JIPMER's genomic TB hub collaborates closely with the ICMR–National Institute for Research in Tuberculosis (ICMR-NIRT, Chennai), formerly the famous Tuberculosis Chemotherapy Centre (1956) that pioneered home-based DOTS therapy.
#18
World Tuberculosis Day (24 March): Observed annually on 24 March to commemorate Dr. Robert Koch's 1882 announcement of the discovery of the tubercle bacillus.

Subject Specialist Commentary

Analytical perspective & practical exam advice from the Master10 academic board

Educator's Insight
Standard rapid TB tests like CBNAAT and TrueNat are brilliant at spotting whether a patient has TB and whether the first-line drug Rifampicin works. However, if a patient has Multi-Drug Resistant TB (MDR-TB), doctors historically had to wait 4 to 8 weeks for slow bacterial cultures to learn which second-line medicines would work. JIPMER Puducherry's Genomic TB Initiative uses Whole Genome and Targeted Next-Generation Sequencing to read all 15+ drug-resistance genes directly from sputum in just 48–72 hours.
For UPSC Prelims, keep three updated clinical and policy facts at your fingertips: (1) MDR-TB means resistance to both Isoniazid and Rifampicin, while XDR-TB adds resistance to a Fluoroquinolone plus a Group A drug (Bedaquiline or Linezolid); (2) India's new all-oral BPaLM regimen cures MDR-TB in 6 months; and (3) Ni-kshay Poshan Yojana nutritional DBT was doubled from ₹500 to ₹1,000/month in November 2024.

Related Knowledge Topics to Discover

Looking for more GK practice?

Explore 52,789+ questions across 65 General Knowledge categories.

Open Interactive Search